Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

ients with advanced kidney cancer. Nexavar inhibits both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in 100 countries.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patients Taking Nexavar

NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Nexavar may cause fetal harm when administered to a pregnant woman. Women of childbearing potential are advised to avoid becoming pregnant and female patients should also be advised against breast-feeding while receiving Nexavar.

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar.

Uncommon but serious adverse reactions including keratoacanthomas/squamous cell cancer of the skin and Stevens - Johnson Syndrome have been reported in clinical trials.

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar. Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required.

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic re
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
(Date:11/24/2014)... Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... , President and CEO of Inovio Pharmaceuticals, will be joined ... ring the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, ... th listing on the Nasdaq Global Select Market.  ... said, "We are honored to ring the Nasdaq Opening Bell ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
(Date:11/24/2014)... New York, NY (PRWEB) November 24, 2014 ... performance, the progressive world of fitness technology will take center ... Living in Digital Times at the 2015 International ... 5:00pm in the Venetian, Level 2, Bellini 2004). The bond ... industry evolves into being less about devices and more about ...
(Date:11/24/2014)... Volpara Solutions announced today that it ... Annual Meeting of the Radiology Society of North ... 1752 – South Hall). Volpara Solutions will showcase ... of its innovative suite of quantitative breast imaging ... measurements of volumetric density, patient-specific dose, breast compression ...
(Date:11/24/2014)... 24, 2014 Olaparib functions as a ... and is one of the first PARP inhibitors. Sufferers ... some types of melanoma, and are often immune to ... gives their malignancies a exclusive weaknesses, as the tissues ... their DNA and allow them to proceed splitting. This ...
(Date:11/24/2014)... Raymond, Alberta (PRWEB) November 24, 2014 ... of people each day. They break up families, ... there is new hope for those that suffer,” ... “Ground-breaking scientific research is showing that our specialized ... , Hardy will appear on “Mind Over Matter”, ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 Gersowitz Libo ... that it has received national Tier recognition in the 2015 ... Achieving a tiered ranking signals a unique combination of quality ... very proud to receive this honor and especially grateful to ... this important honor and ranking possible,” said Jeff S. Korek, ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... ER visits and additional imaging services , CHICAGO, ... quickly could cut by half the amount paid for hospital ... Clinical Congress of the American College of Surgeons. According to ... gallstones at the University of North Carolina in 2008, the ...
... onerous, futile medical interventions are ordered for these end-stage ... -- Many people see end-stage dementia as affecting only ... disease,s effects are far-reaching and eventually fatal. , ... not a terminal condition can have negative ...
... ... organization (PPO) plans in Albany, Essex, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, and Washington counties, ... Medicare Choices individual PPO plans now serve Medicare-eligibles in 23 counties, while its group ... ...
... between brain and device , WEDNESDAY, Oct. 14 (HealthDay ... connections between prosthetic hands and the brain, potentially paving ... type, sense hot and cold, and touch others. , ... "would allow people to have a prosthetic that functions ...
... 14 The National Women,s Law Center,s (NWLC) groundbreaking ... Health Insurance Market Fails Women," first released in ... discriminates against women. Now, this ground-breaking research has resulted ... signed by Governor Schwarzenegger over the weekend -- that ...
... Oct. 14 The Guardian Life Insurance Company of America ... leading provider of employee and voluntary benefits for small and ... products and their sales force according to a study conducted ... that Guardian received "very good to excellent" ratings on all ...
Cached Medicine News:Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 2Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 3Health News:Families Need to Know When Dementia Becomes Terminal 2Health News:Families Need to Know When Dementia Becomes Terminal 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 2Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 4Health News:Fine-Tuning Prosthetic Hands to Restore a Sense of Touch 2Health News:National Women's Law Center Challenges Insurance Industry Practices That Treat Being a Woman Like a 'Pre-Existing Condition' 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 3
... a rapid qualitative test for detection of ... serum samples. It can be used as ... infarction and can be useful to assess ... non-cardiac angina (e.g. gastric pain, strained chest ...
...
...
...
Medicine Products: